LSQLF Meeting: October 2025

The latest Life Sciences Quality Leadership Forum (LSQLF), held on October 2, 2025, brought together leaders across the life sciences sector to explore one of the most transformative topics in regulated environments: the potential role of artificial intelligence in quality management. The discussion centered on the practical use of AI in GxP contexts, the distinctions between generative and agentic approaches, the critical importance of governance and security, and the implications for workforce development and regulatory compliance.

Use Cases: Automating Traceability, Validation, and Compliance

Practical applications of AI are already reshaping quality workflows. One example discussed was a GxP traceability agent designed to act as a virtual auditor. By uploading documents such as URS, FRS, SDS, IQ/OQ/PQ protocols, and trace matrices, quality teams can quickly identify gaps, misalignments, or missing validation evidence.

The agent outputs result in structured formats like charts or heat maps, highlighting whether requirements are fully met, partially met, or missed altogether. Beyond regulatory standards (e.g., Annex 11, GAMP 5, ALCOA+), such tools can also verify compliance with internal SOPs and quality processes – a critical step in audit readiness and risk mitigation.

In another scenario, AI agents reviewed test scripts and validation evidence for completeness, traceability, and justification. This automated review not only increased accuracy but also reduced subjectivity, standardizing the feedback process and enabling faster cross-team alignment.

From Generative to Agentic AI: A Shift in Purpose and Potential

The conversation began by distinguishing two fundamentally different types of AI that are shaping the future of quality operations: generative and agentic AI.

Generative AI excels at producing text, documents, and content from large datasets. However, its limitations – most notably “hallucinations” and unpredictable outputs – make it challenging to use directly in GxP environments where accuracy and traceability are paramount.

Agentic AI, by contrast, is built to support decision-making and autonomous action within defined parameters. Rather than generating new information, agentic systems operate based on established rules, constraints, and workflows. They can, for example, take R&D-developed molecule data and automatically transform it into master data, executable recipes, or structured records for MES, ERP, and LIMS systems.

This decision-making capacity dramatically reduces the manual interpretation steps historically required in technology transfer, change control, and data migration – shifting the human role from execution to oversight.

Security and Governance: Building Trust in AI Systems

Security concerns remain one of the primary barriers to widespread AI adoption in life sciences. Participants emphasized that AI solutions must operate within secure, controlled environments, often behind corporate firewalls and isolated from public networks.

Organizations are increasingly deploying proprietary instances of AI – even when based on licensed platforms – to ensure sensitive data never leaves their environment. This approach mirrors the early evolution of cloud adoption, where dedicated “governed clouds” helped the industry overcome initial security concerns.

Governance is evolving alongside technology. Draft regulatory frameworks, such as Annex 22 in the EU and new FDA guidance, now differentiate between generative and agentic AI and impose stricter requirements around explainability, safety, human oversight, and data provenance. These developments are shaping corporate policies and reinforcing the need for robust risk assessments before deploying AI in regulated contexts.

The Human-in-the-Loop Imperative

Despite its transformative potential, AI in quality operations is not a replacement for human expertise. Regulatory expectations – and operational realities – require a “human-in-the-loop” model, where people review, verify, and approve AI-generated outputs at risk-based checkpoints.

This introduces a new competency challenge: quality professionals must learn how to interpret, validate, and challenge AI decisions rather than simply execute manual tasks. Organizations will need to invest heavily in training to build this capability, as the skills required are fundamentally different from traditional quality review activities.

The concept also raises strategic questions about the future workforce. As AI increasingly automates foundational tasks – such as document review, batch record trending, and environmental data analysis – the opportunities for early-career professionals to build expertise may diminish. This could impact the development of future subject matter experts and leaders, a concern echoed throughout the discussion.

Regulatory Evolution and Risk Appetite

The regulatory landscape is evolving rapidly, with agencies beginning to define boundaries for AI use in GxP operations. Draft guidance suggests that AI systems may not yet be suitable for critical decision-making – such as final batch disposition – but can be deployed in supporting roles to augment and accelerate existing processes.

Risk tolerance will vary by organization. Companies must align their AI strategies with their legal, compliance, and business risk appetites, balancing the efficiency gains of automation against potential regulatory exposure. Early adoption is likely to focus on low-risk, high-value tasks – from document review and data integration to traceability analysis – while more sensitive applications will follow as governance frameworks mature.

The Workforce Challenge: Expertise at Risk

Perhaps the most thought-provoking theme was the impact of AI on workforce development. As agentic systems take over tasks that once formed the foundation of quality and compliance training, organizations risk creating a “missing generation” of experts.

Historically, junior staff built deep expertise by performing manual data analysis, reviewing batch records, or compiling validation evidence. Now, these tasks are increasingly automated – raising questions about how future professionals will develop the skills and judgment needed for senior roles.

This shift is already visible in hiring trends, with companies prioritizing mid- and late-career experts over entry-level hires. While this approach addresses immediate skill needs, it poses a long-term sustainability challenge for the industry.

The Road Ahead: Strategic Adoption and Cultural Change

The integration of AI into GxP quality operations is inevitable – but its success depends on careful strategy, strong governance, and cultural adaptation. Companies must:

• Invest in secure, proprietary AI infrastructure to safeguard sensitive data.
• Develop robust human-in-the-loop frameworks that balance automation with oversight.
• Redefine training and career development pathways to ensure future expertise.
• Engage proactively with regulators to align on evolving expectations.

Just as the industry once transitioned from paper to electronic systems, it is now entering a new era – one where automation, intelligence, and human expertise must coexist in a tightly regulated environment. Those who embrace this shift thoughtfully will not only improve efficiency and compliance but also help shape the next generation of quality operations in life sciences.

Conclusion

The forum underscored a critical truth: AI is not just a tool – it is a catalyst for reimagining how quality is executed, governed, and sustained. By approaching its adoption strategically and responsibly, the life sciences industry can unlock significant value while maintaining the trust, safety, and integrity that are the hallmarks of GxP operations.